Cold Chain Expansion Will Support Cell And Gene Therapies

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

30 Mar 25

Updated

06 Dec 25

Views

44

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

19.6%

7D

-7.4%

Loading

1Y

19.6%

7D

-7.4%

You can edit this narrative until Dec 7 9:05 AM. Then, changes will post as Updates.

Author's Valuation

US$13.2229.5% undervalued

AnalystConsensusTarget Fair Value

Shared on 06 Dec 25

CYRX: Improving Gross Margins And $400 Million Cash Will Drive Upside

Analysts have lifted their price target on Cryoport to $15.00 from $10.00, citing improving gross margins, accelerating product revenue growth, and a solid cash position that helps offset prior policy related concerns. Analyst Commentary Bullish analysts view the recent price target increase as evidence that the market is beginning to look past prior policy related uncertainties and refocus on Cryoport's improving fundamentals.

Shared on 22 Nov 25

CYRX: Rising Gross Margins and $400 Million Cash Will Support Recovery

The analyst consensus price target for Cryoport has increased by $5. This reflects improving gross margins, stronger product revenue growth, and a more favorable market outlook according to analysts.

Shared on 06 Nov 25

Fair value Increased 9.17%

CYRX: Improved Gross Margin And Cash Strength Will Drive Rebound

Analysts have raised their price target for Cryoport by $1.11 to $13.22. They cite improved gross margin, stronger product revenue growth, and increased confidence as market conditions stabilize.

Shared on 07 Aug 25

Fair value Increased 12%

Despite a further deterioration in consensus revenue growth forecasts, Cryoport’s valuation has expanded as reflected in a higher future P/E ratio, resulting in a notable increase in the consensus analyst price target from $10.81 to $12.11. What's in the News Cryoport reiterated its full-year 2025 revenue guidance, expecting total revenue from continuing operations of $165 million to $172 million, representing 5% to 10% year-over-year growth.

Shared on 01 May 25

Fair value Decreased 1.62%

Shared on 24 Apr 25

Fair value Increased 4.67%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 6.33%

Shared on 09 Apr 25

Fair value Increased 4.28%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 1.78%

AnalystConsensusTarget has increased revenue growth from -4.0% to 2.9% and decreased future PE multiple from 25.4x to 21.8x.

AnalystConsensusTarget Fair Value

US$13.22

29.5% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

-0.14%

Life Sciences revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

8.86%

Calculation

US$33.54m

Earnings '28

x

25.38x

PE Ratio '28

=

US$851.44m

Market Cap '28

US$851.44m

Market Cap '28

/

50.55m

No. shares '28

=

US$16.84

Share Price '28

US$16.84 Share Price '28

Discounted to 2025 @ 8.80% p.a.

=

US$13.08

Fair Value '25